SC
MDGL icon

Sophrosyne Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Sophrosyne Capital’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-734
Closed -$111K – 71
2014
Q1 		$111K Buy
+734
New +$145K 0.1% 73

Other funds holding MDGL

CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Sophrosyne Capital's MDGL Position: Q2 2014 in Review

Sophrosyne Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2014, closing a stake of 734 shares — an estimated $111K sold.

Sophrosyne Capital first reported a position in MDGL in Q1 2014 and held it in 1 quarter. The position peaked at $111K in Q1 2014. 82 funds tracked by Wall St. Rank hold MDGL as of Q2 2014.

  • Sophrosyne Capital reported no remaining Madrigal Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Sophrosyne Capital sold 734 Madrigal Pharmaceuticals shares in Q2 2014, an estimated $111K.
  • Sophrosyne Capital first reported a position in Madrigal Pharmaceuticals in Q1 2014 and held it in 1 quarter.
  • Sophrosyne Capital's Madrigal Pharmaceuticals position peaked at $111K in Q1 2014.
  • 82 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2014.

Based on Sophrosyne Capital's 13F filing for Q2 2014, filed 14 Aug 2014.